Evonik Evonik

X
[{"orgOrder":0,"company":"Medicom Healthcare","sponsor":"Famar","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FAMAR and Medicom Healthcare Announce The Acquisition By Medicom Of The Pharmaceutical Dossier Of BIMATOPROST","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Medicom Healthcare

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the agreement, Medicom has acquired the ownership of the pharmaceutical dossier of Zimed (bimatoprost), a preservative free eye drop solution, which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.

            Lead Product(s): Bimatoprost

            Therapeutic Area: Ophthalmology Product Name: Zimed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Famar

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition February 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY